Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi and Lexicon Pharmaceuticals to develop new diabetes therapy

Sanofi and Lexicon Pharmaceuticals to develop new diabetes therapy

10th November 2015

Sanofi and Lexicon Pharmaceuticals have announced a new collaboration to develop a promising oral therapy for diabetes.

The collaboration and license agreement covers the development and commercialisation of sotagliflozin, an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2, which could be a potential treatment option for people with diabetes.

Also known as LX4211, the compound is currently being studied in two pivotal phase III trials in type 1 diabetes, with top-line results expected to be released during the second half of 2016. Phase III trials in type 2 diabetes are expected to begin in 2016.

Sotagliflozin has shown encouraging results in exploratory phase II studies, including reduction of blood sugar, improvement in glycemic variability and reduced meal-time insulin dose compared with placebo in patients with type 1 diabetes, as well as weight loss and blood pressure improvements in type 2 diabetes sufferers.

Pascale Witz, executive vice-president at Sanofi, who will lead its new global diabetes and cardiovascular care business unit, said: "Adding sotagliflozin to our portfolio, which includes medicines at virtually every stage of the treatment pathway, highlights our focus on providing a large and diverse set of therapeutic options for people with this disease."

This comes after the company announced a separate diabetes research collaboration deal with Hanmi Pharmaceutical last week.ADNFCR-8000103-ID-801805344-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.